Zydus Lifesciences reports unaudited results for quarter ended September 30, 2026
Zydus Lifesciences · Pharmaceuticals & Biotechnology
Key highlights
- Board approved unaudited results for quarter and half year ended September 30, 2026, on November 4, 2026
- Consolidated quarter ended 30/09/2026: profit before tax INR 12,617 Million; net profit INR 9,255 Million; basic EPS INR 9.28
- Acquisition of Sterling Biotech Limited's API business completed November 2, 2026; buyback of 8,730,158 shares completed June 18, 2026 for INR 11,063 Million
Why it's rated major development: the year-on-year change is 27% (20% or more for adverse news)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Board Meeting Outcome for Outcome Of Board Meeting Held On November 4, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Zydus Lifesciences
- Acquisition / mergerNotableZydus Lifesciences completes acquisition of Sterling Biotech's API business
Other acquisition / merger filings this fortnight
- Bansal Roofing Products Ltd approves Sept 2026 quarter results and DIPPL stake deal
- NDL Ventures Limited announces NCLT approval of merger with Hinduja Leyland Finance Ltd
- Vintage Coffee and Beverages: Q2 FY27 revenue ₹222.97 Cr; two subsidiaries merged
- S.J.S. Enterprises reports Q2 FY27 revenue up 16.9% YoY and H1 FY27 revenue up 20.4% YoY
- Nykaa reports Q2 FY2027 results; announces 82% stake acquisition in Simply Nam
- Varroc Q2 FY27 revenue up 33.6% YoY to ₹29,479 million; Italy restructuring planned
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.